General Information of Drug (ID: DM2B1V0)

Drug Name
CCT301-38 (targeting ROR2) Drug Info
Indication
Disease Entry ICD 11 Status REF
Renal cell carcinoma 2C90 Phase 1/2 [1]
Cross-matching ID
TTD Drug ID
DM2B1V0

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Ozuriftamab vedotin DMOI00X Head-neck squamous cell carcinoma 2D60.0 Phase 2 [2]
CCT301-59 (targeting ROR2) DM0F9CD Renal cell carcinoma 2C90 Phase 1/2 [1]

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Neurotrophic tyrosine kinase ROR2 (ROR2) TTUDPCI ROR2_HUMAN CAR-T-Cell-Therapy [1]

References

1 ClinicalTrials.gov (NCT03393936) Safety and Efficacy of CCT301 CAR-T in Adult Subjects With Recurrent or Refractory Stage IV Renal Cell Carcinoma
2 Clinical pipeline report, company report or official report of BioAtla